Vyhledat léčivý přípravek pro vzácné onemocnění
Další možnosti vyhledávání
295 Výsledků
Účinné látky
- (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
- (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one
- (S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine
- (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt
- 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt
- 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
- 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker
- 2,2-dimethylbutyric acid, sodium salt
- 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate
- 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride
- 3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid
- 4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid
- 4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1)
- 5-hydroxymethyl-2-furfural
- 6-((3S,4S)-4-methyl-1-(pyrimidin-2-yl-methyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo(1,5-a)pyrazin-8-one
- A highly purified formulation of Staphylococcus aureus protein A
- Acetylsalicylic acid
- Adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene
- Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase
- Adeno-associated viral vector containing the human factor IX gene
- Adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene
- Adeno-associated viral vector serotype 8 containing a functional copy of the codon-optimised F8 cDNA encoding the B-domain deleted human coagulation factor VIII
- Adeno-associated viral vector serotype 8 containing the human factor-VII gene
- Adeno-associated viral vector serotype 8 encoding B-domain deleted liver specific codon optimized bioengineered chimeric human porcine factor VIII, under a synthetic hepatic combinatorial bundle promoter
- Adeno-associated virus vector serotype hu37 encoding human factor VIII
- Afamelanotide
- Afatinib
- Albutrepenonacog alfa
- Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express beta-domain deleted human factor VIII
- Anagrelide hydrochloride
- Antagonist of the complement 5a receptor
- Anti RhO (D) immune globulin intravenous (human)
- Anti-inhibitor coagulant complex
- Anti-von Willebrand Aptamer
- Antihemophilic factor / Von Willebrand factor complex (human)
- Antithrombin III (human)
- Antithrombin alfa
- Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene
- Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene
- Autologous CD34+ cells transduced with the W1.6_hWASP_WPRE lentiviral vector
- Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene
- Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene
- Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene
- Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene
- Autologous CD34+ haematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene
- Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease mRNAs SB-mRENH1 and SB-mRENH2
- Autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene
- Autologous dendritic cells incubated ex vivo with zebularine and factor VIII
- Autologous haematopoietic stem cells transduced with lentiviral vector encoding the human beta-globin gene
- Avatrombopag maleate
- BCX9930
- Bacterial lipase
- Benserazide hydrochloride
- Betaine anhydrous
- Bitopertin
- Bomedemstat ditosilate
- Carglumic acid
- Catridecagog
- Chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451
- Ciclopirox
- Complement factor H
- Coversin
- Danicopan
- Decitabine and tetrahydrouridine
- Deferasirox
- Deferiprone
- Defibrotide
- Desmopressine acetate
- Docosahexaenoic acid ethyl ester
- Eculizumab
- Efgartigimod alfa
- Efmoroctocog alfa
- Eftrenonacog alfa
- Eltrombopag olamine
- Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower
- Factor VIII mimetic bispecific antibody
- Factor XIII A-Subunit (recombinant)
- Factor XIII Concentrate (Human)
- Fedratinib
- Fidanacogene elaparvovec
- Fitusiran
- Fostamatinib disodium
- Gefitinib
- Givinostat
- H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH
- Hemopexin
- Hepcidin mimetic
- Hepcidin mimic peptide
- Human apotransferrin
- Human coagulation factor IX (antihemophilic B factor)
- Human coagulation factor VIII (antihemophilic A factor)
- Human coagulation factor X
- Human coagulation factor XI
- Human erythrocytes encapsulating inositol hexaphosphate
- Human fibrinogen
- Human haptoglobin
- Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
- Human monoclonal IgG2 antibody against tissue factor pathway inhibitor
- Human normal immunoglobulin
- Human plasma derived coagulation protein-Factor XI
- Human platelet antigen-1a immunoglobulin
- Human protein C
- Humanised anti-human Interleukin-6 (IL-6) receptor monoclonal antibody (Genetic Recombination)
- Humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor
- Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa
- Hydroxycarbamide
- Imetelstat
- L-Glutamine
- Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene
- Lentiviral vector containing the human Wiskott Aldrich syndrome protein gene
- Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene
- Lentiviral vector encoding human coagulation factor IX
- Lepirudin
- Levoglutamide
- Lintuzumab
- Liprotamase
- Long acting recombinantFactor VIIa-CTP3
- Luspatercept
- Marzeptacog alfa (activated)
- Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671
- Momelotinib
- Moroctocog alpha
- Myristoylated-peptidyl-recombinant Human CD59
- N-acetyl-D-mannosamine monohydrate
- N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate
- Nanobody directed towards the human A1 domain of von Willebrand factor
- Navitoclax
- Nipocalimab
- Octocog alfa (liposomal)
- Octocog alpha
- PDE9 Inhibitor
- PEGylated peptide inhibitor of complement C3
- Pegylated B-domain-deleted sequence-modified recombinant human factor VIII
- Pegylated carboxyhaemoglobin
- Pegylated proline-interferon alpha-2b
- Pegylated recombinant factor VIIa
- Pegylated recombinant human factor IX
- Plitidepsin
- Poloxamer 188
- Pomalidomide
- Ravulizumab
- Recombinant adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX cDNA (etranacogene dezaparvovec)
- Recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII
- Recombinant coagulation factor VIIa (rFVIIa)
- Recombinant factor VIIa modified with three terminal repeats derived from the beta chain of human chorionic gonadotropin
- Recombinant fusion protein linking human coagulation factor VIIa with human albumin (rVIIa-FP)
- Recombinant human ADAMTS-13
- Recombinant human dyskerin
- Recombinant human lecithin cholesterol acyltransferase
- Recombinant human minibody against complement component C5
- Recombinant human pentraxin-2
- Recombinant human soluble Fc-gamma receptor II b
- Recombinant human von Willebrand factor
- Recombinant microbial lipase
- Recombinant modified ricin toxin A-chain subunit
- Recombinant porcine factor VIII (B domain deleted)
- Rilzabrutinib
- Rituximab
- Rivipansel
- Romiplostim
- Rozanolixizumab
- Ruxolitinib
- S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)
- Sequence-modified human recombinant factor VIIa
- Sevuparin
- Sialic acid
- Siltuximab
- Sirolimus
- Synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a triantennary cluster of N-acetyl galactosamine sugars targeting transmembrane protease, serine 6 mRNA
- Synthetic hepcidin
- Titanium dioxide and bisoctrizole
- Turoctocog alfa pegol
- Vatreptacog alfa (activated)
- Von Willebrand human factor
- Voxelotor
- anti-(integrin beta-3) human monoclonal antibody
- autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene
- autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene
- crizanlizumab
- equine immunoglobulin F(ab')2 fragments targeting Shiga toxin
- mitapivat sulfate
- nonacog alfa
- nonacog gamma
- recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII
- recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant
- recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein
- recombinant human factor IX protein modified with three point mutations
- sutimlimab
- synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues
Obchodní název
- ACLOTINE
- ADAKVEO
- ADVATE
- ADYNOVI
- AFSTYLA
- AGRYLIN
- ALPHANATE
- ALPHANINE
- ALPROLIX
- ANAGRELIDE MYLAN
- ANTI-HUMAN INTERLEUKIN-6 (IL-6) RECEPTOR MONOCLONAL ANTIBODY (GENETICAL RECOMBINATION) CHUGAI PHARMACEUTICAL CO LTD
- ASPAVELI
- ATNATIV
- ATRYN
- BENEFIX
- BESREMI
- BETAFACT
- CABLIVI
- CARBAGLU
- CEPROTIN
- CLOTTAGEN
- COAGADEX
- CORIFACT
- CYSTADANE
- DEFERASIROX MYLAN
- DEFERIPRONE LIPOMED
- DESMOPRESSIN ACETATE AVENTIS BEHRING L.L.C.
- DOPTELET
- DROXIA
- ELOCTA
- ELOCTATE
- ENDARI
- ENDOBULINE
- ENJAYMO
- ESPEROCT
- EXJADE
- Empaveli
- FACTANE
- FACTEUR VII LFB
- FEIBA
- FERRIPROX
- FLEBOGAMMA DIF
- GAMMAGARD
- GAMMAPLEX
- HAEMOCOMPLETTAN
- HELIXATE NEXGEN
- HEMLIBRA
- HEMOLEVEN
- HUMATE -P
- HYDREA
- IBLIAS
- IDELVION
- INREBIC
- INTRAGLOBIN F
- JAKAFI
- JAKAVI
- JIVI
- KASKADIL
- KIOVIG
- KOGENATE BAYER
- KOVALTRY
- NILEVAR
- NONAFACT
- NOVOEIGHT
- NOVOSEVEN
- NOVOSEVEN RT
- NOVOTHIRTEEN
- NPLATE
- OBIZUR
- OCTAGAM
- OCTIM
- OXBRYTA
- PRIVIGEN
- PROMACTA
- PROTEXEL
- Provayblue
- Pyrukynd
- REBLOZYL
- REFACTO AF
- REFIXIA
- REFLUDAN
- REFLUDEN
- REVOLADE
- RIASTAP
- RIXUBIS
- SANDOGLOBULINE
- SIKLOS
- SOLIRIS
- SYLVANT
- TAVALISSE
- TEGELINE
- TEPADINA
- THROMBATE III
- TRETTEN
- ULTOMIRIS
- VEYVONDI
- VONCENTO
- VONJO
- VONVENDI
- WILFACTIN
- WILSTART
- WINRHO SD
- XAGRID
- XROMI
- XURIDEN
- ZYNTEGLO